Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
13MAY

CellCentric raises Europe's largest 2026 biotech round

4 min read
20:05UTC

CellCentric closed a $220m Series D on 5 May led by Venrock Healthcare Capital Partners, with Pfizer and Fidelity co-investing: Europe's largest private biotech financing of 2026, drawn entirely from private capital.

← Back to State capital lands on UK tech in nine daysJump to analysis ↓
TechnologyDeveloping
Key takeaway

CellCentric's $220m Series D with Pfizer proves UK oncology commands US-sized rounds without public subsidy.

CellCentric closed a $220m Series D on 5 May 2026, which BioSpace and BioPharma Dive reported as the largest private biotech financing in Europe in 2026. 1 Venrock Healthcare Capital Partners led; Fidelity Management and Research, Sofinnova Partners, HBM Healthcare, RA Capital Management, Forbion, Pfizer, Avego BioScience Capital, and the American Cancer Society BrightEdge initiative co-invested.

The capital funds Phase 2 DOMMINO-1 trials, running in both the UK and the United States, for inobrodib, an oral p300/CBP (a histone acetyltransferase target) inhibitor for relapsed and refractory multiple myeloma. Phase 3 (DOMMINO-2) is planned for H2 2026. inobrodib's oral formulation is clinically significant: multiple myeloma treatment is predominantly infusion-based today, and an oral option changes the outpatient economics of treatment substantially for a patient population that requires long-term maintenance therapy.

Pfizer's entry at Phase 2 stage is the signal that compresses the typical trade-sale timeline. When a major pharmaceutical company enters a Series D alongside a Phase 2 readout, it is typically conducting buy-versus-build analysis in parallel: the equity position gives Pfizer visibility into the DOMMINO-1 data before it is public. For CellCentric, that creates a dual path to liquidity: a Phase 3 success that supports an independent listing, or an acquisition by a strategic already inside the syndicate.

No UK public investor participated in the round. CellCentric kept its Phase 2 and capital fully in the UK without any state anchor. At $220m with Pfizer in, public capital was neither needed nor sought. The FCA and PRA had cut SM&CR (Senior Managers and Certification Regime) certification roles by 15% on 22 April , reducing regulatory overhead for authorised financial participants in biotech rounds, a signal that the UK regulatory environment is loosening at both the investment and company level simultaneously. UK oncology founders with credible Phase 2 data can now argue for a US-sized Series D from London; the Boston relocation pressure has dropped a notch.

Deep Analysis

In plain English

CellCentric is developing a cancer drug called inobrodib for multiple myeloma, a blood cancer that affects the bone marrow. Inobrodib is taken as a tablet rather than an infusion, which matters enormously for patients who need long-term treatment: monthly infusion clinic visits over years are exhausting and disruptive to daily life. The company raised $220m in May 2026, described as the largest private funding round for a European biotech company in 2026. Pfizer, one of the world's largest pharmaceutical companies, invested alongside US and European specialist healthcare funds. The money funds Phase 2 clinical trials in the UK and US, with a larger Phase 3 global trial planned for the second half of 2026. No UK government money joined the round; the BBB's £40m-per-company cap would have covered less than 20% of the $220m raise, and Venrock, Pfizer, and Fidelity filled the syndicate without it.

Deep Analysis
Root Causes

Multiple myeloma's relapsed/refractory segment represents a structural market failure in oncology: patients exhaust approved therapies faster than new approvals arrive, creating a persistent unmet need that Pfizer, J&J, and BMS have all tried to address through acquisitions and licensing.

CellCentric's oral formulation addresses a specific constraint in the relapsed segment: patients receiving maintenance therapy over years find infusion-based treatments logistically unsustainable, and an oral agent that maintains efficacy while eliminating infusion clinic visits has health-economics advantages independent of clinical differentiation.

The DOMMINO-1 Phase 2 running simultaneously in the UK and US is a regulatory strategy as much as a clinical one: dual-jurisdiction Phase 2 data compresses the time to Biologics License Application in the US while supporting a UK Medicines and Healthcare products Regulatory Agency (MHRA) submission from the same dataset.

What could happen next?
  • Opportunity

    Pfizer's Series D equity position creates a structured acquisition option that CellCentric can exercise via a Phase 3 success: a bilateral deal with Pfizer already inside the syndicate avoids a competitive auction process and provides balance-sheet certainty for the development programme.

  • Consequence

    CellCentric's $220m with no BBB participation, on the same day as Cytospire's oversubscribed BBB-backed round, establishes that UK oncology companies with credible Phase 2 assets do not require public co-investment to close US-scale rounds; the BBB's additionality case is stronger in early-stage rounds where private lead investors are absent.

Sources:BioSpace
Mentions:inobrodib →CellCentric →Venrock Healthcare Capital Partners →Pfizer →Sofinnova Partners →Forbion →Phase 3 →Senior Managers and Certification Regime →United States →Boston →Paris →Nasdaq →Fidelity →American Cancer Society BrightEdge →BioSpace →BioPharma Dive →HBM Healthcare →RA Capital Management →Avego BioScience Capital →
First Reported In

Update #4 · State capital lands on UK tech in nine days

BioSpace· 13 May 2026
Read original →
Different Perspectives
Fubon Financial
Fubon Financial
Fubon Financial joined Humanoid's Series A on 21 July as a minority financial investor alongside Schaeffler and Bosch, who also hold the customer and manufacturer roles. A pure-play investor from Taipei is pricing a London robot maker on terms two German industrial groups effectively set.
NATO Innovation Fund
NATO Innovation Fund
The Fund joined Greenjets' £30m Series A on 21 July alongside NSSIF, betting on ducted electric propulsion's civil market to fund a technology with an obvious defence application. It is backing a company that took twenty-one years to reach this stage, on the expectation that certification-cycle timelines reward patient capital over a quick return.
Prime Movers Lab
Prime Movers Lab
Prime Movers Lab led Humanoid's Series A on 21 July as the round's only pure financial investor, sharing the cap table with two co-investors who are also the anchor customer and the factory. That leaves the fund's usual arm's-length pricing role diluted by partners with a direct commercial stake in the valuation holding up.
Bosch and Schaeffler
Bosch and Schaeffler
Schaeffler signed what Humanoid calls the industry's largest publicly announced commercial agreement, while Bosch took equity and became contract manufacturer, filling capacity a shrinking combustion supply chain freed. Neither company has disclosed a unit count or an invoice, so their public commitment stops well short of Forbes' 100,000-unit projection.
UK founders raising seed through Series A
UK founders raising seed through Series A
A London robotics founder raised $152m this week against a signed industrial customer and a reserved factory, while a Cornwall founder more typically draws a £25,000 loan from a regional fund manager. Both call it British venture funding, but one route runs through Bosch's production line and the other through diligence built for businesses too small for any VC's attention.
EQT
EQT
EQT was reported on 3 July to be in advanced talks for a further CuspAI stake on behalf of the EU's Scaleup Europe Fund, but does not appear on the round CuspAI closed. Whether Europe's own sovereign vehicle secured a position, was outbid, or withdrew is unresolved.